Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus rituximab versus mycophenolate plus steroids in severe systemic lupus erythematosus
2018-001392-21Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in systemic lupus erythematosus (SLE) comparing Belimumab plus rituximab with Mycophenolate plus steroids (2 arms). Primary endpoint: Treatment failure rate during 2 years. Started Sep 2018; status: active.
02
Drugs
belimumabrituximabmycophenolate
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-001392-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001392-21.